Myelofibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Research Reports
Feb 13, 2022
Primary myelofibrosis is an uncommon disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in the United States. The median length of survival for patients with primary myelofibrosis is 3.5-5.5 years. The 5-year survival rate is about half of that expected for age- and sex-matched controls. Fewer than 20% of patients are expected to be alive at 10 years. The common causes of death in patients with primary myelofibrosis are infections, hemorrhage, cardiac failure, post-splenectomy mortality, and transformation into acute leukemia. Leukemic transformation occurs in approximately 20% of patients with primary myelofibrosis within the first 10 years.
Read more:- Myelofibrosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Comprehensive insight on patient segmentation based on age, sex, types (Primary Myelofibrosis, Secondary Myelofibrosis) and progression of Polycythemia Vera (PV), Essential Thrombocythemia (ET) into MF. Biomarker: (JAK2 (Janus Kinase 2)-V617F, CALR (Calreticulin-R), MPL (Myeloproliferative Leukaemia virus gene MPL515L/K and others). Signs & Symptoms, Clinical Manifestations, Treatment types have been provided in the epidemiology section of the MYELOFIBROSIS and its treatment in the 8 MM coun-tries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China
In terms of pharmacologic therapies, there are few drug candidates are in different Phase (Phase I, II & III) stages of development. Key companies are, Pharmaxis Ltd: PXS-5505, Incyte Corpo-ration: Ruxolitinib, Celgene: Fedratinib, AbbVie: Ruxolitinib Navi-toclax, NS Pharma, Inc.:NS-018, Sumitomo Dainippon Pharma Oncology: TP-3654, Sierra Oncology: Momelotinib, CTI BioPharma: Pacritinib, Imago BioSciences: IMG-7289, Samus Therapeutics, PU-H71, Constellation Pharmaceuticals: CPI-0610. Looking at the current clinical development and assets progress card, it would really be a great opportunity for the pharmaceutical company to build products around the treatment of MYELOFI-BROSIS specifically for moderate to severe patients. Therapies that target other pathways that may be abnormally activated in MF are also being tested. LCL-161 is an oral therapy that blocks the activity of an inhibitor of apoptosis (IAP) proteins, which promote cell survival. SL-401 is a therapy that targets the IL-3 receptor, which is found on the surface of MF cells.
About Thelansis:
Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.
Other Reports:-
Platinum-resistant ovarian cancer – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Multiple Myeloma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Dyskeratosis Congenita – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Dercum Disease – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Idiopathic hypersomnia (IH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030
Contact details:-
Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India
Contact no.: +91(124) 404-1731
Sales office
183-Asylum Street Hartford, CT-06103, USA
USA +1 (267) 244-6955,
clientsupport@thelansis.com
m.berg@thelansis.com
Contact Information:
m.berg@thelansis.com
Tags:
PR-Wirein, Menafn, Reportedtimes, iCN Internal Distribution, Research Newswire, English
YOU MAY ALSO LIKE
Marine Collagen Market Set to Reach USD…
Primary myelofibrosis is an uncommon disease, with an annual incidence of approximately 0.5-1.5 cases per 100,000 individuals in the United States. The median length of…
read more